Abstract:

AIM: To observe the clinical efficacy and safety of azithromycin combined with ambroxol hydrochloride in treatment of mycoplasma pneumonia children with acute bronchial pneumonia.  METHODS: One hundred and four mycoplasma pneumonia children with bronchial pneumonia were randomly divided into control group and treatment group, fifty-two cases for each group. The control group was given azithromycin 10 mg/kg, qd, intravenous drip; and the treatment group was given azithromycin 10 mg/kg+ambroxol hydrochloride 15 mg, qd, intravenous drip. After 7d treatment, the clinical efficacy and occurrence of adverse drug reactions were observed. The levels of serum hypersensitive C-creactive protein (hsCRP), gamma interferon (IFN-γ), procalcitonin (PCT), immunoglobulin A(IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) were compared. RESULTS:After 7 d treatment, the total effective rate in treatment group and control group were 96.15%（50/52） and 82.69%（43/52）, the difference was statistically significant (P<0.05). The hsCRP of treatment group and control group were (13.28±4.76) and (21.11±6.42) mg/L; IFN-γ were (8.45±3.62) and (20.36±5.12) ng/L; PCT were (4.02±2.07) and (7.46±2.13) μg/L; IgA were (2.17±0.43) and (4.03±0.52) μg/L; IgG were (8.14±1.31) and (12.32±1.65) μg/L; IgM were (0.86±0.28) and (1.20±0.39) μg/L, respectively, the differences were all statistically significant (P<0.05). The adverse drug reactions were mainly nausea, vomiting, rash, diarrhea, dizziness, drowsiness, the incidence of adverse drug reactions in treatment group and control group were 23.08% and 19.23%, respectively, the difference has no statistically significant difference (P>0.05). CONCLUSION: The azithromycin combined with ambroxol hydrochloride in treatment of mycoplasma pneumonia children with acute bronchial pneumonia have significantly curative effect, which can reduce the patients' inflammation, improve immune function, and have no increasing the adverse drug reactions.

Key words: azithromycin, ambroxol hydrochloride, mycoplasma pneumonia, acute bronchial pneumonia, inflammation factors, immune function